Neurogene Inc.
Neurogene Inc. (NGNE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NGNE · as of Jun 8, 2026
Key Statistics
Explore Neurogene Inc. Data
ngne stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The NGNE analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $69.50, representing +162.36% upside from the current price of $26.49.
Competitors & Peers
ngne competitorsNGNE
ADCT
ALMS
AUTL
BNTC
FULCStock Performance
Full HistoryAbout Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy …
what is neurogene inc. · ngne stock overview · neurogene inc. company profile · who is neurogene inc. ceo · ngne NASDAQ · neurogene inc. headquarters · neurogene inc. business segments
About Stock Overview & Key Data
Neurogene Inc. (NGNE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 7, 2014. As of the latest trading session, NGNE stock price is $26.49, with a market capitalization of $418.6M. The stock has returned +33.05% over the past 12 months and +28.59% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Neurogene Inc. stock is Buy, with an average 12-month price target of $69.50. In fiscal year 2025, Neurogene Inc. reported revenue of — and net income of -$90.4M. For detailed data — including Neurogene Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Neurogene Inc. (NGNE) stock price is $26.49. The stock is traded on NASDAQ under the ticker symbol NGNE. The 52-week range is $14.65 – $37.27.